Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Biotechnology

Healthcare
$162.86 -0.45%

-$0.71 today

Market cap
$16.48B
Beta
0.40
P/E (TTM)
23.8
EPS (TTM)
$6.65
52W Low $122.14High $169.57

Volume 1.60M

Average 1.18M

NBIX EBITDA Margin

EBITDA as a percentage of revenue.

Neurocrine Biosciences, Inc.NASDAQ: NBIX

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to 29.5%

EBITDA Margin was 29.5% in Q3 FY2026, down 8.2 pp from a year earlier. On a trailing-twelve-month basis it was 25.7%, up 0.3 pp year over year. Over 3 fiscal years it widened by 7.4 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 18 analysts of 27.1% for the fiscal year ending Dec 2026, up from 23.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
29.5%+9.7 pp QoQ
Last fiscal yearDec 2025
23.3%-3.9 pp YoY
LTMSep 2026
25.7%+0.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-8.2 pp+1.4 pp+9.5 pp
1 year-3.9 pp+3.8 pp+7.7 pp
3 years+7.4 pp+22.3 pp+14.9 pp
5 years+12.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
23.3%
Year-over-year change
-3.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NBIX compares with its peers on the latest reported figures

  • NBIX's LTM Sep 2026 EBITDA Margin of 25.7% is the highest of the 7 companies compared; the peer median is -12.3%.
  • Its year-over-year change of +0.3 pp is the 3rd highest of 6, against a peer median of -1.1 pp.
  • Over three fiscal years its change of +7.4 pp compares with a peer median of -17.1 pp.
NBIX Competitors Peer median
EBITDA Margin for NBIX and competitors
Company Period LTM level YoY 3-year change
NBIXNeurocrine Biosciences, Inc.LTM Sep 202625.7% +0.3 pp+7.4 pp
JAZZJazz Pharmaceuticals plcLTM Sep 202621.0% +14.8 pp-34.0 pp
ACADACADIA Pharmaceuticals Inc.LTM Sep 202611.7% -1.1 pp+54.9 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-1.9% -26.9 pp-17.1 pp
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-22.7% +23.5 pp+324.2 pp
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-62.6% -41.0 pp-64.2 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-590.7% ——
BHVNBiohaven Ltd.FY2025— ——
GHRSGH Research PLCFY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding NBIX) -12.3%-1.1 pp-17.1 pp

Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.13B1.49B1.89B2.36B2.86B
Cost of Revenue14.3M23.2M39.7M34M52.1M
Gross Profit1.12B1.47B1.85B2.32B2.81B
Gross Margin98.7%98.4%97.9%98.6%98.2%
Research & Development328.1M463.8M565M731.1M1.02B
Selling, General & Admin583.3M752.7M887.6M1.01B1.16B
Operating Expenses1.02B1.22B1.6B1.75B2.19B
Depreciation & Amortization10.9M15.6M21.3M27.1M30.1M
EBITDA138.1M236.6M416.1M639.7M666.6M
EBITDA Margin12.2%15.9%22.0%27.2%23.3%
Operating Income102.5M249M250.9M570.5M619.1M
Operating Margin9.0%16.7%13.3%24.2%21.6%
Interest Income011.2M091M90.3M
Interest Expense25.8M7.1M4.6M126.6M0
Other Income / Expenses(1.1M)(35.1M)81.2M(84.5M)86.3M
Income Before Tax101.4M213.9M332.1M486M705.4M
Pre-Tax Margin8.9%14.4%17.6%20.6%24.7%
Income Tax Expense11.8M59.4M82.4M144.7M226.8M
Net Income89.6M154.5M249.7M341.3M478.6M
Net Margin7.9%10.4%13.2%14.5%16.7%
EPS (Basic)0.951.612.563.404.81
EPS (Diluted)0.921.562.473.294.67
Weighted Avg Shares94.6M95.8M97.7M100.4M99.5M
Weighted Avg Shares (Diluted)97.9M98.9M101M103.7M102.5M

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Intrinsic Alpha fair value

Locked

Current Price

$162.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.